Key Insights

Highlights

Treatment Research

2 treatments under study, led by Nivolumab

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Not Yet Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07902921Phase 1/2Not Yet Recruiting

STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

Showing all 1 trials

Research Network

Common Treatments

  • Nivolumab1
  • Star06021

Active Sponsors

  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Lung Cancer1
  • Metastatic Castrateresistant Prostate Cancer1
  • Mcrpc1
  • Nonsmall Cell Lung Cancer1
  • Nsclc1

Activity Timeline